Reply to Richie and Villasante

Comment

Ann Duerr et al. J Infect Dis. 2013.

. 2013 Feb 15;207(4):690-2.

doi: 10.1093/infdis/jis738. Epub 2012 Nov 29.

No abstract available

Comment on

Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study).
Duerr A, Huang Y, Buchbinder S, Coombs RW, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson MN; Step/HVTN 504 Study Team. Duerr A, et al. J Infect Dis. 2012 Jul 15;206(2):258-66. doi: 10.1093/infdis/jis342. Epub 2012 May 4. J Infect Dis. 2012. PMID: 22561365 Free PMC article. Clinical Trial.
Use of adenovirus serotype 5 vaccine vectors in seropositive, uncircumcised men: safety lessons from the step trial.
Richie TL, Villasante EF. Richie TL, et al. J Infect Dis. 2013 Feb 15;207(4):689-90. doi: 10.1093/infdis/jis737. Epub 2012 Nov 29. J Infect Dis. 2013. PMID: 23204174 No abstract available.

1. Richie T, Villasante E. Use of adenovirus serotype 5 vaccine vectors in seropositive, uncircumcised men: safety lessons from the Step trial. J Infect Dis. 2013;207:689–90. - PubMed
1. Duerr A, Huang Y, Buchbinder S, Coombs R, Lawrence D, Sanchez J, del Rio C, Casapia M, Santiago S, Gilbert P, Corey L, Robertson M for the Step/ HVTN 504 study team. Extended follow-up of participants in a cell-mediated immunity HIV vaccine trial (Step study): Vaccine effect on HIV acquisition among men wanes over time. J Infect Dis. 2012;206:258–266. - PMC - PubMed